You can read our Premium News Service in full if you have an Annual Subscription to the OTCToolbox website. You can read Basic News stories free of charge.
11 April 2022
GlaxoSmithKline (GSK) Consumer Healthcare is considering a licensing deal for Cann Group’s cannabidiol (CBD) capsule in Australia and other markets worldwide.
16 March 2022
GlaxoSmithKline (GSK) has appointed six directors to the Board of Haleon, the standalone company that will be formed through the planned demerger of GSK Consumer Healthcare in July 2022.
3 March 2022
GlaxoSmithKline (GSK) expects to demerge its Consumer Healthcare business as Haleon in July 2022, and has set out how the standalone company plans to achieve “above-market sales growth”.
3 March 2022
Increasing household penetration for its brands will be the “largest opportunity” for GlaxoSmithKline (GSK) Consumer Healthcare following its demerger as Haleon in July 2022, according to Brian McNamara, chief executive officer designate of Haleon.
3 March 2022
Switching medicines from prescription to non-prescription status and launching naturals will be high on the agenda at GlaxoSmithKline (GSK) Consumer Healthcare following its demerger as Haleon in July 2022, says Brian McNamara, chief executive officer designate of Haleon.
22 February 2022
Haleon will be the new name for GlaxoSmithKline (GSK) Consumer Healthcare following the planned demerger of the business in mid-2022.
15 February 2022
GlaxoSmithKline (GSK) is in “full countdown mode” to demerging its Consumer Healthcare business, according to chief executive officer Emma Walmsley, who was speaking as the business reported sales up by a tenth at constant exchange rates in the fourth quarter of 2021.
19 January 2022
Unilever has said it “will not increase” its offer for GlaxoSmithKline (GSK) Consumer Healthcare above GBP50 billion (USD68 billion).
17 January 2022
Unilever sees consumer health as an “attractive strategic option”, and says GlaxoSmithKline (GSK) Consumer Healthcare would be a “strong strategic fit”.
17 January 2022
GlaxoSmithKline (GSK) has rejected three Unilever takeover offers for its Consumer Healthcare business, including one worth GBP50 billion (USD68 billion).